<DOC>
	<DOCNO>NCT01102335</DOCNO>
	<brief_summary>The purpose study elucidate influence anti-hepatitis B virus therapy safety survival HCC patient transcatheter arterial chemoembolization .</brief_summary>
	<brief_title>Synergistic Treatment Hepatocellular Carcinoma ( HCC ) Using Transcatheter Arterial Chemoembolization ( TACE ) With Anti-hepatitis B Virus ( Anti-HBV ) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>hepatocellular carcinoma treat transcatheter arterial chemoembolization ( TACE ) HBVDNA &gt; 10^3copies/mL , include alanine aminotransferase ( ALT ) normal patient expect survive time &gt; 1 year HBV marker positive ( anyone HbsAg , HbsAb , HbeAg , HbeAb HbcAb ) antiviral therapy history alanine aminotransferase ( ALT ) &gt; 400 U/L serum total bilirubin &gt; 50 Î¼mol/L HBVDNA &gt; 10^9copies/mL extrahepatic metastasis main portal vein embolus apparent cardiac pulmonary dysfunction liver function : Child B Child C HCV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>hepatitis B virus</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Liver Neoplasms</keyword>
	<keyword>Drug Toxicity</keyword>
	<keyword>Survival</keyword>
</DOC>